Company Description
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States.
The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple-negative breast cancer; ABV-1504, which has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients.
It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer.
ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation.
ABVC BioPharma, Inc. is headquartered in Fremont, California, and operates as a subsidiary of YuanGene Corporation.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Uttam Patil |
Contact Details
Address: 44370 Old Warm Springs Boulevard Fremont, California 94538 United States | |
| Phone | 510 668 0881 |
| Website | abvcpharma.com |
Stock Details
| Ticker Symbol | ABVC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001173313 |
| CUSIP Number | 00091F106 |
| ISIN Number | US00091F3047 |
| Employer ID | 26-0014658 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Uttam Yashwant Patil Ph.D. | Chief Executive Officer and Interim Chief Financial Officer |
| Eugene Jiang | Chairman and Chief Business Officer |
| Dr. Tsung-Shann Jiang EMBA, Ph.D. | Chief Scientific Officer, Chief Strategy Officer and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 30, 2025 | 8-K/A | [Amend] Current report |
| May 27, 2025 | POS AM | Post-Effective amendments for registration statement |
| May 27, 2025 | POS AM | Post-Effective amendments for registration statement |
| May 27, 2025 | POS AM | Post-Effective amendments for registration statement |
| May 22, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| May 20, 2025 | EFFECT | Notice of Effectiveness |
| May 20, 2025 | EFFECT | Notice of Effectiveness |
| May 16, 2025 | DEF 14A | Other definitive proxy statements |
| May 16, 2025 | POS AM | Post-Effective amendments for registration statement |
| May 16, 2025 | POS AM | Post-Effective amendments for registration statement |